VSIG4, a B7 family–related protein, is a negative regulator of T cell activation
J. Clin. Invest. Lorenz Vogt, et al. 116:2817 doi:10.1172/JCI25673 [Go to this article.]

Figure 5
VSIG4 inhibits T cell proliferation and IL-2 production in vitro. (A) Plates were coated with anti-CD3 at the indicated concentrations in the presence of 5 μg/ml VSIG4-Ig or control IgG1. Proliferation of purified CD4⁺ T cells was monitored after 2 days by [³H]thymidine incorporation. (B) Plates were coated with anti-CD3 at 0.5 μg/ml in the presence of 5 or 10 μg/ml VSIG4-Ig or IgG1 at the indicated concentrations. CD8⁺ T cell proliferation was monitored after 2 days by [³H]thymidine incorporation. (C) Costimulation assays were performed with purified CD4⁺ T cells with a fixed concentration of anti-CD3 (0.5 μg/ml) in the presence or absence of anti-CD28 (2 μg/ml) with either 5 μg/ml VSIG4-Ig or control IgG1. (D) IL-2 production of CD4⁺ T cells stimulated with 0.5 μg/ml anti-CD3 in the presence of 5 μg/ml VSIG4-Ig or control IgG1. (E) Proliferation assays were performed in the presence of 0.5 μg/ml anti-CD3 and VSIG4-Ig, PD-L1–Ig, PD-L2–Ig, or control IgG1 at a concentration of 10 μg/ml. (F) Proliferation assays were performed in the presence of 0.5 μg/ml anti-CD3 and VSIG4-Ig or control IgG1 at a concentration of 5 or 10 μg/ml in the absence or presence of 10 ng/ml IL-2. Error bars represent standard deviations for data from experiments performed in triplicate. Representative data from least 2 independent experiments are shown. The difference between VSIG4-Ig– and IgG1-treated cells was significant in all panels shown (P < 0.05). In F, the difference between VSIG4-Ig– and IgG1-treated cells in the presence of IL-2 was not significant (P > 0.05).